BRCA1 and ovarian carcinoma: The results of the Phase II trial, presented at ASCO 2009, primarily aimed to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced chemotherapy-refractory ovarian cancer [86].